ArticleRheumatology and therapy2025

Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial.

Ning Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.